⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Procos S.p.A. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Procos S.p.A.
↗Cameri, Italy
Procos S.p.A. is a prominent Contract Development and Manufacturing Organization (CDMO) established in 1945. The company specializes in the development, scale-up, and production of Active Pharmaceutical Ingredients (APIs), Highly Potent Active Pharmaceutical Ingredients (HPAPI), advanced intermediates, and linker-payloads for the global pharmaceutical industry.
Headquartered in Cameri, Italy, Procos operates a 155,000 square meter multipurpose plant designed under cGMP compliance. The facility is equipped with 560 m3 of reactor capacity and is audited by major regulatory bodies including the FDA, EMA, and PMDA. Procos is a wholly owned subsidiary of the Japanese CBC Co. Ltd Group.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Founded:1945
Ownership:subsidiary
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A
Modalities:Small molecule, HPAPI, Linker-payloads
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:CBC Co. Ltd Group
Acquired By:CBC Co. Ltd Group
Key Partnerships:CBC Co. Ltd Group (Parent)
COMPETITION
Position:Niche Player
Competitors:Laurus Labs, Symbiotec, Hikal
LEADERSHIP
Key Executives:
Enrico Zodio - CEO
Kingo Yamashita - Chief Commercial Officer
Yoshihiro Furukawa - CFO
LINKS
Website:procos.it
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Procos S.p.A.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.